<DOC>
	<DOCNO>NCT02456714</DOCNO>
	<brief_summary>Cholangiocarcinoma , malignant gastrointestinal tumor low incidence poor prognosis . Chemotherapy common treatment advanced disease . On basis phase III clinical study , cisplatin plus gemcitabine consider standard first-line treatment advance cholangiocarcinoma patient , establish second line therapy . Since fluorouracil leucovorin combine irinotecan oxaliplatin ( FOLFIRINOX ) appear safe demonstrate efficacy clinical study advance pancreatic cancer , colorectal cancer phase I study cholangiocarcinoma , combination could effective second-line treatment patient advance cholangiocarcinoma .</brief_summary>
	<brief_title>Second Line Chemotherapy FOLFIRINOX Irresectable Cholangiocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>Histological cytological diagnosis cholangiocarcinoma . Metastatic disease irresectable locally advanced cholangiocarcinoma . Measurable disease accord RECIST criterion version 1.1 . Age 18 75 year . WHO/ECOG performance status 02 . Patients receive least 3 cycle gemcitabine/cisplatin first line . Adequate hematological function ( WBC &gt; 3.0 x 109/L , platelet &gt; 100 x109/L ) Adequate hepatic function ( bilirubin ≤ 1.5 x upper normal limit ( ULN ) ; ALAT ASAT &lt; 5x ULN case liver metastases &lt; 2.5 x ULN absence liver metastasis . Adequate renal function ( creatinine clearance &gt; 60 ml/min ; creatinine &lt; 120 µmol/L ) Absence cardiac insufficiency , chest pain ( medically control ) myocardial infarction 12 month precede study entry . Signed informed consent . Concurrent secondary malignancy malignancy within 3 year prior enter study exception nonmetastatic basal cell squamous cell skin cancer carcinoma situ cervix treat conebiopsy resection Presence cerebral meningeal metastasis Contraindication substance plan treatment . History chronic diarrhea colorectal inflammatory condition , unresolved occlusion subocclusion symptomatic treatment administer Active infection serious underlying condition may prevent patient receive plan treatment . For example : prolong unresolved bacterial cholangitis destruction bile duct branch ( e.g . endoprosthesis insertion ) two cholangitis last 6 month . Patients active uncontrolled severe infection , cirrhosis chronic active hepatitis exclude . Presence cardiac insufficiency , unstable angina pectoris , symptomatic congestive heart , failure myocardial infarction 6 month prior randomization , serious uncontrolled cardiac arrhythmia . Inclusion another investigational clinical trial Women pregnant , breastfeed use adequate contraceptive Age young 18 old 76 year Individuals correctional supervision guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>FOLFIRINOX</keyword>
	<keyword>Phase II study</keyword>
</DOC>